Publicacións (12) Publicacións de Laura Cotovad Bellas

2024

  1. Ultrarapid Insulin Use Can Reduce Postprandial Hyperglycemia and Late Hypoglycemia, Even in Delayed Insulin Injections: A Connected Insulin Cap-Based Real-World Study

    Diabetes Technology and Therapeutics, Vol. 26, Núm. 1, pp. 1-10

2023

  1. Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial

    Diabetes Care, Vol. 46, Núm. 1, pp. 206-208

  2. GALIPDIA study: Reaching lipid targets in a population with type 2 diabetes (T2DM) from the Northwest of Spain

    Endocrinologia, Diabetes y Nutricion, Vol. 70, Núm. 1, pp. 29-38

  3. IDF2022-0315 Efficacy of the insulin pen cap Insulclock® in type 1 diabetes mellitus (T1DM): A multicenter, randomized clinical trial

    Diabetes Research and Clinical Practice, Vol. 197, pp. 110301

  4. LATE HYPOGLYCEMIA AFTER INSULIN INJECTION IS RELATED TO INJECTION TIME. AN INSULCLOCK® CONNECTED INSULIN CAP-BASED REAL-WORLD STUDY

    DIABETES TECHNOLOGY & THERAPEUTICS, Vol. 25, Núm. Suppl 2, pp. A82-A82

2022

  1. EFFICACY OF THE INSULIN PEN SMART CAP INSULCLOCK® IN PEOPLE WITH NON-CONTROLLED TYPE 1 DIABETES MELLITUS (T1DM): A MULTICENTER, RANDOMIZED CLINICAL TRIAL

    DIABETES TECHNOLOGY & THERAPEUTICS, Vol. 24, Núm. Suppl. 1, pp. A77-A77

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

2020

  1. The challenge of diabetes home control in COVID-19 times: Proof is in the pudding

    Diabetes Research and Clinical Practice, Vol. 168

2019

  1. Dieta y excreción de catecolaminas

    Nutrición y dietética clínica (Elsevier), pp. 649-653

2014

  1. Dieta y excreción de catecolaminas

    Nutrición y dietética clínica (Elsevier), pp. 559-562

2008

  1. Benefits of Orlistat beyond the weight loss

    INTERNATIONAL JOURNAL OF OBESITY, Vol. 32, Núm. Suppl. 1, pp. S120-S120

  2. Comparative meta-analysis to evaluate systolic and diastolic blood pressure in obese patients treated with orlistat 120 mg, rimonabant, sibutramine or placebo

    INTERNATIONAL JOURNAL OF OBESITY, Vol. 32, Núm. Suppl. 1, pp. S109-S109